Loading…

BeiGene and Amgen announced a global strategic oncology collaboration for the commercialization and development of three Amgen drugs in China and joint development of 20 pipeline assets. Amgen will purchase a 20.5% stake in BeiGene for approximately $2.7 billion.
“BeiGene, Ltd. and Amgen today announced a global strategic oncology collaboration for the commercialization and development in China of Amgen’s XGEVA, KYPROLIS, and BLINCYTO”nasdaq.com
Summarized from public sources; check the original articles before acting on it.